We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+17.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.54B
AUM Growth
+$331M
Cap. Flow
-$396M
Cap. Flow %
-6.06%
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$49.7M
2
GEHC icon
GE HealthCare
GEHC
+$36.6M
3
MRNA icon
Moderna
MRNA
+$34.7M
4
BHVN icon
Biohaven
BHVN
+$33.4M
5
BSX icon
Boston Scientific
BSX
+$28M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.4M
2
UNH icon
UnitedHealth
UNH
+$64M
3
EVH icon
Evolent Health
EVH
+$36.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.5M
5
HUM icon
Humana
HUM
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Industrials 0.83%
3 Energy 0.03%
4 Consumer Discretionary 0.02%
5 Communication Services 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$441M 6.74%
8,713,987
-519,713
-6% -$24.9M
ARGX icon
2
argenx
ARGX
$53.8B
$331M 5.06%
869,208
-42,322
-5% -$19.7M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$320M 4.9%
2,430,500
-153,050
-6% -$17.6M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$300M 4.58%
736,390
-266,345
-27% -$98.4M
ISRG icon
5
Intuitive Surgical
ISRG
$122B
$281M 4.29%
832,041
+3,042
+0.4% +$907K
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$220M 3.36%
3,066,400
-103,850
-3% -$5.97M
MRNA icon
7
Moderna
MRNA
$24.5B
$190M 2.9%
1,908,420
+413,095
+28% +$34.7M
BSX icon
8
Boston Scientific
BSX
$65.4B
$183M 2.8%
3,170,603
+524,308
+20% +$28M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$169M 2.59%
885,318
-9,027
-1% -$1.54M
ABT icon
10
Abbott
ABT
$175B
$169M 2.59%
1,535,656
-25,312
-2% -$2.53M
RVMD icon
11
Revolution Medicines
RVMD
$39.6B
$146M 2.23%
5,091,000
+369,500
+8% +$8.88M
SYK icon
12
Stryker
SYK
$123B
$139M 2.13%
465,724
-9,889
-2% -$2.78M
INCY icon
13
Incyte
INCY
$23.4B
$135M 2.07%
2,156,719
-334,731
-13% -$18.9M
AXNX
14
DELISTED
Axonics, Inc. Common Stock
AXNX
$114M 1.75%
1,833,165
-419,686
-19% -$23.5M
DXCM icon
15
DexCom
DXCM
$29.6B
$113M 1.74%
914,593
+228,860
+33% +$23.4M
ARVN icon
16
Arvinas
ARVN
$517M
$103M 1.58%
2,507,731
+382,531
+18% +$8.94M
CLDX icon
17
Celldex Therapeutics
CLDX
$2.77B
$95.8M 1.47%
2,416,296
+516,296
+27% +$15.2M
MGNX icon
18
MacroGenics
MGNX
$285M
$95.8M 1.46%
9,953,313
+150,000
+2% +$1.04M
BDX icon
19
Becton Dickinson
BDX
$43.6B
$94.6M 1.45%
388,068
+83,838
+28% +$20.7M
AGIO icon
20
Agios Pharmaceuticals
AGIO
$2.36B
$89.3M 1.37%
4,011,000
-2,500
-0.1% -$56K
MDT icon
21
Medtronic
MDT
$106B
$80M 1.22%
970,772
+329,280
+51% +$25.1M
EVH icon
22
Evolent Health
EVH
$654M
$78.5M 1.2%
2,376,992
-1,300,123
-35% -$36.8M
EW icon
23
Edwards Lifesciences
EW
$49.4B
$77.7M 1.19%
1,018,998
-6,459
-0.6% -$449K
EXAS
24
DELISTED
Exact Sciences
EXAS
$77.5M 1.19%
1,047,786
-72,033
-6% -$4.72M
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$76.1M 1.16%
3,513,351
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2023 Portfolio in Review

As of Q4 2023, Bellevue Group held 179 positions worth $6.54B, up 5.3% from $6.21B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Bellevue Group withdrew a net $396M in Q4 2023, closing 18 positions and reducing 89 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $34.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Biohaven worth $46M.

  • Bellevue Group's largest Q4 2023 buy was Biohaven: 1,075,000 shares worth $46M.
  • Bellevue Group added most to Immunocore in Q4 2023, an estimated $49.7M increase.
  • Bellevue Group's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $98.4M.
  • Bellevue Group fully exited Jazz Pharmaceuticals in Q4 2023, selling an estimated $34.5M.
  • Bellevue Group's ten largest holdings make up 40% of its $6.54B portfolio in Q4 2023.
  • Bellevue Group opened 25 new positions and closed 18 in Q4 2023.
  • Bellevue Group's portfolio value rose 5.3% quarter-over-quarter to $6.54B.

Based on Bellevue Group's 13F filing for Q4 2023, filed 14 Feb 2024.